Transplantation tolerance in pediatric recipients: Lessons and challenges

Pediatric Transplantation

Volumn 9, Issue 1, 2005, Pages 17-27

  Tinckam, Kathryn J ^a   Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Immunosuppression; Tolerance; Tolerance trials; Transplantation

Indexed keywords

ANTIGEN RECOGNITION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; ORGAN TRANSPLANTATION; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE;

ANIMALS; CHILD; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MAJOR HISTOCOMPATIBILITY COMPLEX; PATIENT SELECTION; SELF TOLERANCE; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE;

EID: 13744259771     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00220.x     Document Type: Review

References (121)

1. MICHON L, HAMBURGER J, OECONOMOS N, et al. An attempted kidney transplantation in man: Medical and biological aspects. Presse Med 1953: 61: 1419-1423.
2. GUILD WR, HARRISON JH, MERRILL JP, MURRAY J. Successful homotransplantation of the kidney in an identical twin. Trans Am Clin Climatol Assoc 1955: 67: 167-173.
3. BILLINGHAM RE, BRENT L, MEDEWAR PB. Actively acquired tolerance of foreign cells. Nature 1953: 172: 603-606.
4. BRENT L. The 50th anniversary of the discovery of immunologic tolerance. N Engl J Med 2003: 349: 1381-1383.
5. STROBER S, DHILLON M, SCHUBERT M, et al. Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N Engl J Med 1989: 321: 28-33.
6. SAYEGH MH, FINE NA, SMITH JL, RENNKE HG, MILFORD EL, TILNEY NL. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991: 114: 954-955.
7. SPITZER TR, DELMONICO F, TOLKOFF-RUBIN N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999: 68: 480-484.
8. BUHLER LH, SPITZER TR, SYKES M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002: 74: 1405-1409.
9. SALAMA AD, REMUZZI G, HARMON WE, SAYEGH MH. Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001: 108: 943-948.
10. NEYLAN JF, SAYEGH MH, COFFMAN TM, et al. The allocation of cadaver kidneys for transplantation in the United States: Consensus and controversy. ASN Transplant Advisory Group. American Society of Nephrology. J Am Soc Nephrol 1999: 10: 2237-2243.
11. HARIHARAN S, JOHNSON CP, BRESNAHAN BA, TARANTO SE, MCINTOSH MJ, STABLEIN D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000: 342: 605-612.
12. WINKELMAYER WC, WEINSTEIN MC, MITTLEMAN MA, GLYNN RJ, PLISKIN JS. Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 2002: 22: 417-430.
13. LOUBEAU PR, LOUBEAU JM, JANTZEN R. The economics of kidney transplantation versus hemodialysis. Prog Transplant 2001: 11: 291-297.
14. SULEYMANLAR G, TUNCER M, SARIKAYA M, et al. The cost effectiveness of mycophenolate mofetil in the first year after living related renal transplantation. Transplant Proc 2001: 33: 2780-2781.
15. WHITING JF, ZAVALA EY, ALEXANDER JW, FIRST MR. The cost-effectiveness of transplantation with expanded donor kidneys. Transplant Proc 1999: 31: 1320-1321.
16. MATTHEWS JB, RAMOS E, BLUESTONE JA. Clinical trials of transplant tolerance: Slow but steady progress. Am J Transplant 2003: 3: 794-803.
17. NICKERSON PW, STEURER W, STEIGER J, STROM TB. In pursuit of the "holy grail": Allograft tolerance. Kidney Int Suppl 1994: 44: S40-S49.
18. SUTHANTHIRAN M. Transplantation tolerance: Fooling mother nature. Proc Natl Acad Sci USA 1996: 93: 12072-12075.
19. KIRK AD. Immunosuppression without immunosuppression? How to be a tolerant individual in a dangerous world. Transpl Infect Dis 1999: 1: 65-75.
20. VINCENTI F. Immunosuppression minimization: Current and future trends in transplant immunosuppression. J Am Soc Nephrol 2003: 14: 1940-1948.
21. CALNE RY. Prope tolerance: A step in the search for tolerance in the clinic. World J Surg 2000: 24: 793-796.
22. BURLINGHAM WJ, JANKOWSKA-GAN E, VANBUSKIRK A, OROSZ CG, LEE JH, KUSAKA S. Loss of tolerance to a maternal kidney transplant is selective for HLA class II: Evidence from trans-vivo DTH and alloantibody analysis. Hum Immunol 2000: 61: 1395-1402.
23. VAN PARIJS L, ABBAS AK. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science 1998: 280: 243-248.
24. WALDMANN H. Transplantation tolerance - where do we stand? Nat Med 1999: 5: 1245-1248.
25. LI XC, STROM TB, TURKA LA, WELLS AD. T cell death and transplantation tolerance. Immunity 2001: 14: 407-416.
26. KAPPLER JW, ROEHM N, MARRACK P. T cell tolerance by clonal elimination in the thymus. Cell 1987: 49: 273-280.
27. DAVIS MM, BJORKMAN PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988: 334: 395-402.
28. SPRENT J, GAO EK, WEBB SR. T cell reactivity to MHC molecules: Immunity versus tolerance. Science 1990: 248: 1357-1363.
29. BLACKMAN M, KAPPLER J, MARRACK P. The role of the T cell receptor in positive and negative selection of developing T cells. Science 1990: 248: 1335-1341.
30. ANDERSON G, MOORE NC, OWEN JJ, JENKINSON EJ. Cellular interactions in thymocyte development. Annu Rev Immunol 1996: 14: 73-99.
31. POULIN JF, VISWANATHAN MN, HARRIS JM, et al. Direct evidence for thymic function in adult humans. J Exp Med 1999: 190: 479-486.
32. GOODNOW CC, CYSTER JG, HARTLEY SB, et al. Self-tolerance checkpoints in B lymphocyte development. Adv Immunol 1995: 59: 279-368.
33. KRENSKY AM. Immunologic tolerance. Pediatr Nephrol 2001: 16: 675-679.
34. CYSTER JG, ANSEL KM, REIF K, et al. Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev 2000: 176: 181-193.
35. BUHL AM, NEMAZEE D, GAMBIER JC, RICKERT R, HERTZ M. B-cell antigen receptor competence regulates B-lymphocyte selection and survival. Immunol Rev 2000: 176: 141-153.
36. MANILAY JO, PEARSON DA, SERGIO JJ, SWENSON KG, SYKES M. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 1998: 66: 96-102.
37. CHARLTON B, AUCHINCLOSS H Jr, FATHMAN CG. Mechanisms of transplantation tolerance. Annu Rev Immunol 1994: 12: 707-734.
38. FOSTER RD, PHAM S, LI S, AITOUCHE A. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. Transplantation 2003: 76: 988-994.
39. WEKERLE T, SAYEGH MH, HILL J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998: 187: 2037-2044.
40. STARZL TE, DEMETRIS AJ, MURASE N, ILDSTAD S, RICORDI C, TRUCCO M. Cell migration, chimerism, and graft acceptance. Lancet 1992: 339: 1579-1582.
41. STARZL TE, DEMETRIS AJ, MURASE N, THOMSON AW, TRUCCO M, RICORDI C. Donor cell chimerism permitted by immunosuppressive drugs: A new view of organ transplantation. Immunol Today 1993: 14: 326-332.
42. THOMAS JM, CARVER FM, KASTEN-JOLLY J, et al. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation 1994: 57: 101-115.
43. STROBER S, BENIKE C, KRISHNASWAMY S, ENGLEMAN EG, GRUMET FC. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: Studies of chimerism and anti-donor reactivity. Transplantation 2000: 69: 1549-1554.
44. NORIS M, CUGINI D, CASIRAGHI F, et al. Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation. J Am Soc Nephrol 2001: 12: 2815-2826.
45. ANDERSON CC, MATZINGER P. Immunity or tolerance: Opposite outcomes of microchimerism from skin grafts. Nat Med 2001: 7: 80-87.
46. MONACO AP. Chimerism in organ transplantation: Conflicting experiments and clinical observations. Transplantation 2003: 75: 13S-16S.
47. SAYEGH MH, TURKA LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998: 338: 1813-1821.
48. HAMAD AR, SCHNECK JP. Antigen-induced T cell death is regulated by CD4 expression. Int Rev Immunol 2001: 20: 535-546.
49. WEAVER CT, HAWRYLOWICZ CM, UNANUE ER. T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells. Proc Natl Acad Sci USA 1988: 85: 8181-8185.
50. CHEN W, ISSAZADEH S, SAYEGH MH, KHOURY SJ. In vivo mechanisms of acquired thymic tolerance. Cell Immunol 1997: 179: 165-173.
51. DALLMAN MJ, SHIHO O, PAGE TH, WOOD KJ, MORRIS PJ. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991: 173: 79-87.
52. GIANELLO PR, BLANCHO G, FISHBEIN JF, et al. Mechanism of cyclosporin-induced tolerance to primarily vascularized allografts in miniature swine. Effect of administration of exogenous IL-2. J Immunol 1994: 153: 4788-4797.
53. SAYEGH MH, PERICO N, GALLON L, et al. Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. Transplantation 1994: 58: 125-132.
54. SURI-PAYER E, AMAR AZ, THORNTON AM, SHEVACH EM. CD4 + CD25 + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998: 160: 1212-1218.
55. OLUWOLE SF, OLUWOLE OO, DEPAZ HA, ADEYERI AO, WITKOWSKI P, HARDY MA. CD4 + CD25 + regulatory T cells mediate acquired transplant tolerance. Transpl Immunol 2003: 11: 287-293.
56. SALAMA AD, NAJAFIAN N, CLARKSON MR, HARMON WE, SAYEGH MH. Regulatory CD25 + T cells in human kidney transplant recipients. J Am Soc Nephrol 2003: 14: 1643-1651.
57. SUCIU-FOCA N, MANAVALAN JS, CORTESINI R. Generation and function of antigen-specific suppressor and regulatory T cells. Transpl Immunol 2003: 11: 235-244.
58. ROTROSEN D, MATTHEWS JB, BLUESTONE JA. The immune tolerance network: A new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol 2002: 110: 17-23.
59. JONULEIT H, SCHMITT E, KAKIRMAN H, STASSEN M, KNOP J, ENK AH. Infectious tolerance: Human CD25 (+) regulatory T cells convey suppressor activity to conventional CD4 (-) T helper cells. J Exp Med 2002: 196: 255-260.
60. ONODERA K, LEHMANN M, AKALIN E, VOLK HD, SAYEGH MH, KUPIEC-WEGLINSKI JW. Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J Immunol 1996: 157: 1944-1950.
61. ONODERA K, HANCOCK WW, GRASER E, et al. Type 2 helper T cell-type cytokines and the development of "infectious" tolerance in rat cardiac allograft recipients. J Immunol 1997: 158: 1572-1581.
62. KIRK AD. Crossing the bridge: Large animal models in translational transplantation research. Immunol Rev 2003: 196: 176-196.
63. WILLIAMS MA, ONAMI TM, ADAMS AB, et al. Cutting edge: Persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002: 169: 5387-5391.
64. KIM SK, BREHM MA, WELSH RM, SELIN LK. Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation. J Immunol 2002: 169: 90-98.
65. BLATTMAN JN, ANTIA R, SOURDIVE DJ, et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med 2002: 195: 657-664.
66. COSSARIZZA A, ORTOLANI C, PAGANELLI R, et al. CD45 isoforms expression on CD4 + and CD8 + T cells throughout life, from newborns to centenarians: Implications for T cell memory. Mech Ageing Dev 1996: 86: 173-195.
67. WILLIAMS MA, TRAMBLEY J, HA J, et al. Genetic characterization of strain differences in the ability to mediate CD40/ CD28-independent rejection of skin allografts. J Immunol 2000: 165: 6849-6857.
68. ADAMS AB, WILLIAMS MA, JONES TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003: 111: 1887-1895.
69. MONTGOMERY SP, MOG SR, Xu H, et al. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant 2002: 2: 381-385.
70. OCHIAI T, GUNJI Y, NAGATA M, KOMORI A, ASANO T, ISONO K. Effects of rapamycin in experimental organ allografting. Transplantation 1993: 56: 15-19.
71. FISHBEIN JM, ROSENGARD BR, GIANELLO P, et al. Development of tolerance to class II-mismatched renal transplants after a short course of cyclosporine therapy in miniature swine. Transplantation 1994: 57: 1303-1308.
72. UTSUGI R, BARTH RN, LEE RS, et al. Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully mhc-mismatched kidney allografts in miniature swine. Transplantation 2001: 71: 1368-1379.
73. HOMAN WP, FRENCH ME, MILLARD P, DENTON TG, FABRE JW, MORRIS PJ. Studies on the effects of cyclosporin A upon renal allograft rejection in the dog. Surgery 1980: 88: 168-173.
74. TOLEDO-PEREYRA LH, BANDLIEN KO, MACKENZIE GH, GORDON DA. Orthotopic liver transplantation. Various immunosuppressive regimens to improve survival. Am Surg 1984: 50: 258-263.
75. JONKER M, VAN DE HOUT Y, NEUHAUS P, et al. Complete withdrawal of immunosuppression in kidney allograft recipients: A prospective study in rhesus monkeys. Transplantation 1998: 66: 925-927.
76. CHO CS, BURKLY LC, FECHNER JH Jr, et al. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients. Transplantation 2001: 72: 587-597.
77. CHEN H, PENG J, LUO H, et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. Transplantation 2000: 69: 1555-1561.
78. LENSCHOW DJ, WALUNAS TL, BLUESTONE JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996: 14: 233-258.
79. LECHLER R, NG WF, STEINMAN RM. Dendritic cells in transplantation-friend or foc? Immunity 2001: 14: 357-368.
80. THOMSON AW, LU L. Dendritic cells as regulators of immune reactivity: Implications for transplantation. Transplantation 1999: 68: 1-8.
81. DAVIDSON A, DIAMOND B. Autoimmune diseases. N Engl J Med 2001: 345: 340-350.
82. BURLINGHAM WJ, GRAILER AP, FECHNER JH Jr, et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995: 59: 1147-1155.
83. MILLAN MT, SHIZURU JA, HOFFMANN P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002: 73: 1386-1391.
84. TRIVEDI HL, SHAH VR, VANIKAR AV, et al. High-dose peripheral blood stem cell infusion: A strategy to induce donor-specific hyporesponsiveness to allografts in pediatric renal transplant recipients. Pediatr Transplant 2002: 6: 63-68.
85. KENYON NS, CHATZIPETROU M, MASETTI M, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 1999: 96: 8132-8137.
86. KIRK AD, BURKLY LC, BATTY DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999: 5: 686-693.
87. LI Y, LI XC, ZHENG XX, WELLS AD, TURKA LA, STROM TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999: 5: 1298-1302.
88. KNECHTLE SJ, FECHNER JH Jr, DONG Y, et al. Primate renal transplants using immunotoxin. Surgery 1998: 124: 438-446 (discussion; 446-447).
89. CONTRERAS JL, ECKHOFF DE, CARTNER S, et al. Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplant recipients. Transplantation 1999: 68: 215-219.
90. KAWAI T, ANDREWS D, COLVIN RB, SACHS DH, COSIMI AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000: 6: 114.
91. STARZL TE, MURASE N, ABU-ELMAGD K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003: 361: 1502-1510.
92. CALNE R, MOFFATT SD, FRIEND PJ, et al. Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Nippon Geka Gakkai Zasshi 2000: 101: 301-306.
93. RAO V, PIRSCH JD, BECKER BN, KNECHTLE SJ. Sirolimus monotherapy following Campath-1H induction. Transplant Proc 2003: 35: S128-S130.
94. KIRK AD, HALE DA, MANNON RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003: 76: 120-129.
95. TERASAKI PI, OZAWA M. Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 2004: 4: 438-443.
96. BAID S, SAIDMAN SL, TOLKOFF-RUBIN N, et al. Managing the highly sensitized transplant recipient and B cell tolerance. Curr Opin Immunol 2001: 13: 577-581.
97. THERUVATH TP, SAIDMAN SL, MAUIYYEDI S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001: 72: 77-83.
98. MONTGOMERY RA, ZACHARY AA, RACUSEN LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch-positive recipients. Transplantation 2000: 70: 887-895.
99. KAWAI T, SACHS DH, COSIMI AB. Tolerance to vascularized organ allografts in large-animal models. Curr Opin Immunol 1999: 11: 516-520.
100. DENTON MD, MAGEE CC, SAYEGH MH. Immunosuppressive strategies in transplantation. Lancet 1999: 353: 1083-1091.
101. OJO AO, MEIER-KRIESCHE HU, HANSON JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000: 69: 2405-2409.
102. WOMER KL, VELLA JP, SAYEGH MH. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol 2000: 20: 126-147.
103. KASISKE BL, CHAKKERA HA, ROEL J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000: 11: 1735-1743.
104. LARSEN CP, ELWOOD ET, ALEXANDER DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996: 381: 434-438.
105. KAWAI T, COSIMI AB, COLVIN RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995: 59: 256-262.
106. SHO M, SANDNER SE, NAJAFIAN N, et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002: 236: 667-675.
107. DADHANIA D, MUTHUKUMAR T, DING R, et al. Molecular signatures of urinary cells distinguish acute rejection of renal allografts from urinary tract infection. Transplantation 2003: 75: 1752-1754.
108. LI B, HARTONO C, DING R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001: 344: 947-954.
109. STROM TB, SUTHANTHIRAN M. Prospects and applicability of molecular diagnosis of allograft rejection. Semin Nephrol 2000: 20: 103-107.
110. NEUBERGER J, ADAMS DH. What is the significance of acute liver allograft rejection? J Hepatol 1998: 29: 143-150.
111. CECKA JM, GJERTSON DW, TERASAKI PI. Pediatric renal transplantation: A review of the UNOS data. United Network for Organ Sharing. Pediatr Transplant 1997: 1: 55-64.
112. SIEDERS E, PEETERS PM, TENVERGERT EM et al. Retransplantation of the liver in children. Transplantation 2001: 71: 90-95.
113. LAPCHAK PH, BRISCOE DM. Hyporesponsiveness in pediatric recipients. Pediatr Transplant 2002: 6: 8-11.
114. WYSOCKA J, HASSMANN E, LIPSKA A, MUSIATOWICZ M. Naive and memory T cells in hypertrophied adenoids in children according to age. Int J Pediatr Otorhinolaryngol 2003: 67: 237-241.
115. AZUMA H, CHANDRAKER A, NADEAU K, et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996: 93: 12439-12444.
116. SHIRASUGI N, ADAMS AB, DURHAM MM, et al. Prevention of chronic rejection in murine cardiac allografts: A comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol 2002: 169: 2677-2684.
117. SCHWARZE ML, MENARD MT, FUCHIMOTO Y, et al. Mixed hematopoietic chimerism induces long-term tolerance to cardiac allografts in miniature swine. Ann Thorac Surg 2000: 70: 131-138 (discussion; 138-139).
118. RUSSELL PS, CHASE CM, SYKES M, ITO H, SHAFFER J, COLVIN RB. Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol 2001: 167: 5731-5740.
119. SAYEGH MH, CARPENTER CB. Tolerance and chronic rejection. Kidney Int Suppl 1997: 58: S11-S14.
120. TURGEON NA, IWAKOSHI NN, PHILLIPS NE, et al. Viral infection abrogates CD8 (+) T-cell deletion induced by costimulation blockade. J Surg Res 2000: 93: 63-69.
121. FISHMAN JA, RUBIN RH. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1741-1751.